CTLA4 and neoplasm: Furthermore they showed that in situ tumor ablation can be combined with immunomodulation via checkpoint inhibition (anti-CTLA-4) or regulatory T-cell depletion to enhance the CD8+ T-cell activation and clinical response [17].